Skip to main content
Enter your The Contraceptive Pipeline Database username.
Enter the password that accompanies your username.
Miglustat, N-butyldeoxynojirimycin (NB-DNJ)
Zavesca, a medication already approved for treating a rare genetic disorder, works as a male contraceptive for a particular strain of laboratory mouse. Exactly how Zavesca acts as a contraceptive for the mice is not known.
May 30, 2018
Active Pharmaceutical Ingredient (API):
Potential Multi-Purpose Technology (MPT):
University of Washington
Research on Zavesca as a male contraceptive has stopped as it was shown to not be effective in humans.
Download Product Report